Race and genomics

New England Journal of Medicine

Volumn 348, Issue 12, 2003, Pages 1166-1170

  Cooper, Richard S ^a   Kaufman, Jay S ^b   Ward, Ryk ^c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b IL   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MICROSATELLITE DNA;

DISEASE PREDISPOSITION; DNA SEQUENCE; DRUG MARKETING; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HUMAN; PRIORITY JOURNAL; RACE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION;

BIOLOGY; CONTINENTAL POPULATION GROUPS; DRUG THERAPY; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOMICS; HUMANS; SOCIOLOGY;

EID: 0037456771     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMsb022863     Document Type: Review

References (31)

1. Montagu A, ed. The concept of race. New York: Free Press of Glencoe, 1964.
2. Risch N, Burchard E, Ziv E, Tang H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol 2002;3(7):comment2007.1-comment2007.12.
3. Muntaner C, Nieto FJ, O'Campo P. The Bell Curve: on race, social class, and epidemiologic research. Am J Epidemiol 1996;144:531-6.
4. Wade N. Race is seen as real guide to track roots of disease. New York Times. July 30, 2002:F1.
5. Franciosa JA, Taylor AL, Cohn JN, et al. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002;8:128-35.
6. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilatorheart failure trials. J Card Fail 1999;5:178-87.
7. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
8. Dries DL, Strong M, Cooper RS, Drazner MH. Efficacy ofangiotensin-converting enzyme inhibition in reducing progression of asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002;40:311-7. [Erratum, J Am Coll Cardiol 2002;40:1019.]
9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor of calcium channel blocker vs diuretic: the Antihypertensive and lipid-lowering treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. [Erratum, JAMA 2003;289:178.]
10. Wilson JE, Weale ME, Smith AC, et al. Population genetic structure of variable drug response. Nat Genet 2001;29:265-9.
11. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002;297:1333-6.
12. Rosenberg NA, Pritchard JK, Weber JL, et al. Genetic structure ofhuman populations. Science 2002;298:2381-5.
13. Stephens JC, Schneider JA, Tanguay DA, et al. Haplotype variation and linkage disequdibrium in 313 human genes. Science 2001;293:489-93. [Erratum, Science 2001;293:1048.]
14. Halushka MK, Fan J-B, Bentley K, et al. Patterns ofsingle-nucleotide polymorphisms in candidate genes for blood pressure homeostasis. Nat Genet 1999;22:239-47.
15. Templeton AR, Human races: a genetic and evolutionary perspective. Am Anthropol 1998;100:632-50.
16. Romualdi C, Balding D, Nasidze IS, et al. Patterns of human diversity, within and among cotinents, inferred from biallelic DNA polymorphisms. Genome Res 2002;12:602-12.
17. Freedman BI. End-stage renal failure in African Americans: insights in kidney disease susceptibility. Nephrol Dial Transplant 2002;17:198-200.
18. Yancy CW. The role ofrace in heart failure therapy. Curr Cardiol Rep 2002;4:218-25.
19. Hajjar RJ, MacRae CA. Adrenergic-receptor polymorphisms and heart failure. N Engl J Med 2002;347:1196-9.
20. Henderson SO, Coetzee GA, Ross RK, Yu MC, Henderson BE. Elevated mortality rates from circulatory disease in African American men and women of Los Angeles County, California - a possible genetic susceptibility? Am J Med Sci 2000;320:18-23.
21. The HGP: end of phase 1. Nat Genet 2002;30:125.
22. Kimm SYS, Glynn NW, Aston CE, et al. Racial differences in the relation between uncoupling protein genes and resting energy expenditure. Am J Clin Nutr 2002;75:714-9.
23. Robbins AS, Whittemore AS, Thom DH. Differences in socioeconomic status and survival amongwhite and black men with prostate cancer. Am J Epidemiol 2000;151:409-16.
24. Brancati FL, Whelton PK, Kuller LH, Klag MJ. Diabetes mellitus, race, and socioeconomic status: a population-based study. Ann Epidemiol 1996;6:67-73.
25. Brewster LM, Clark JF, van Montfrans GA. Is greater tissue activity of creatine kinase the genetic factor increasing hypertension risk in black people of sub-Saharan African descent? J Hypertens 2000;18:1537-44.
26. Grim CE, Robinson M. Blood pressure variation in blacks: genetic factors. Semin Nephrol 1996;16:83-93.
27. Chase A. The legacy of Malthus: the social costs of the new scientific racism. New York: Alfred A. Knopf, 1977.
28. Gould SJ. The mismeasure of man. Rev. ed. New York: W.W. Norton, 1996.
29. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure ofhaplotype blocks in the human genome. Science 2002;296:2225-9.
30. Cooper R, Rotimi C, Ataman S, et al: The prevalence of hypertension in seven populations of West African origin. Am J Public Health 1997;87:160-8.
31. Cooper RS, Rotimi CN, Kaufman JS, et al. Prevalence of NIDDM among populations of the African diaspora. Diabetes Care 1997;20: 343-8.